# ë°°ê²½ ìë£Œ: Session 3 - Host-Pathogen Interaction

**ì„¸ì…˜**: Session 3: Host-Pathogen Interaction
**ì—°ì‚¬**: Eun-Kyeong Jo (Chungnam Natl. Univ.), Jung-Hyun Kim (Ajou Univ.), Hyunjung Lee (Institut Pasteur Korea)
**ì¼ì‹œ**: 2025ë…„ 10ì›” 30ì¼ (ëª©) 15:10-16:25
**ì¥ì†Œ**: ì„±ê· ê´€ëŒ€í•™êµ ì˜ê³¼ëŒ€í•™, AI ê°•ì˜ì‹¤ 3304

**ì¤‘ìš”ë„**: â­â­â­â­â­ (96/100ì )

---

## ğŸ¯ ì„¸ì…˜ ê°œìš”

### ì™œ ì´ ì„¸ì…˜ì´ ì¤‘ìš”í•œê°€?

**1. ìˆ™ì£¼-ë³‘ì›ì²´ ìƒí˜¸ì‘ìš©ì˜ í•µì‹¬ ë©”ì»¤ë‹ˆì¦˜ì„ ë‹¤ë£¬ë‹¤**
- AutophagyëŠ” ì„¸í¬ê°€ mycobacteriaë¥¼ ì œê±°í•˜ëŠ” ì¤‘ìš”í•œ ë°©ì–´ ê¸°ì „
- 2025ë…„ Nature Communications: ATG7 ê²°í• ì‹œ NTM ê°ì—¼ ì•…í™”
- Host-directed therapyì˜ í•µì‹¬ í‘œì  (mTOR, AMPK ì¡°ì ˆ)
- Post-COVID-19 ì‹œëŒ€, mycobacteria ê°ì—¼ ê´€ë¦¬ì˜ ìƒˆë¡œìš´ ì „ëµ

**2. ì°¨ì„¸ëŒ€ ì§ˆë³‘ ëª¨ë¸ ê¸°ìˆ ì„ ì œì‹œí•œë‹¤**
- Human pluripotent stem cell (hPSC) ê¸°ë°˜ organoid ì‹œìŠ¤í…œ
- Tissue-resident macrophage í¬í•¨ (in vivoì— ê°€ì¥ ê·¼ì ‘)
- 2024ë…„ Cell Stem Cell: ë°”ì´ëŸ¬ìŠ¤ ê°ì—¼ ì‹œ ë©´ì—­ ë§¤ê°œ ì†ìƒ ëª¨ë¸ë§
- ë§ˆìš°ìŠ¤ë¥¼ ë„˜ì–´ì„  ì¸ê°„ íŠ¹ì´ì  ë°˜ì‘ ì—°êµ¬ ê°€ëŠ¥

**3. ì‹ ì•½ ê°œë°œ íŒŒì´í”„ë¼ì¸ì˜ ë³‘ëª©ì„ í•´ê²°í•œë‹¤**
- ì „í†µì  HTS (high-throughput screening)ì˜ hit rate: 0.87%
- ìƒˆë¡œìš´ ê°ì—¼ ëª¨ë¸: Staphylococcus aureus ex vivo GFP ì‹œìŠ¤í…œ
- ê¸°ê³„ í•™ìŠµ ê²°í•© ì‹œ hit rate 14ë°° í–¥ìƒ (2024ë…„ PLOS Comput Biol)
- ì•½ë¬¼ ë°œê²¬ ë¹„ìš© ë° ì‹œê°„ ëŒ€í­ ê°ì†Œ

**4. í¬ë‹¥ ì—°êµ¬ìì—ê²Œ í•„ìˆ˜ì ì¸ ì²¨ë‹¨ ê¸°ìˆ ê³¼ í”Œë«í¼ì„ ì†Œê°œí•œë‹¤**
- Organoid ì œì‘ ê¸°ìˆ  (iPSC differentiation â†’ macrophage â†’ assembly)
- ê°ì—¼ ëª¨ë¸ ìµœì í™” (multiplicity of infection, ì¸¡ì • ì‹œì )
- High-content imagingê³¼ AI ë¶„ì„
- ì‚°í•™ì—° í˜‘ë ¥ ëª¨ë¸ (Institut Pasteur Koreaì˜ ì‚¬ë¡€)

---

## ğŸŒŸ ì‰¬ìš´ë§ í’€ì´ (ì„¸ì…˜ ì „ì²´)

### ì´ ì„¸ì…˜ì€ ì‰½ê²Œ ë§í•˜ë©´...

**í•œ ì¤„ ìš”ì•½**: "ì„¸ê· ê³¼ ì¸ì²´ì˜ 'ì „íˆ¬'ë¥¼ ì´í•´í•˜ê³ , ê·¸ ì „íˆ¬ë¥¼ ì¬í˜„í•˜ëŠ” ë” ë‚˜ì€ 'ì‹¤í—˜ì‹¤ ëª¨ë¸'ì„ ë§Œë“¤ì–´ì„œ, ì‹ ì•½ì„ ë¹ ë¥´ê³  ì •í™•í•˜ê²Œ ì°¾ëŠ” ë°©ë²•"

### ğŸ¬ ìˆ™ì£¼-ë³‘ì›ì²´ ìƒí˜¸ì‘ìš© - ì´ì•¼ê¸°ë¡œ ì´í•´í•˜ê¸°

**[1ì¥: ìˆ™ì£¼ì˜ ë¹„ë°€ ë¬´ê¸° - Autophagy]**

**ë°°ê²½**: ì„¸í¬ ì†ì— ìˆ¨ê²¨ì§„ ì¬í™œìš© ì‹œìŠ¤í…œ

ìš°ë¦¬ ëª¸ì˜ ì„¸í¬ëŠ” ëŠì„ì—†ì´ ë‹¨ë°±ì§ˆì„ ë§Œë“¤ê³ , ì‚¬ìš©í•˜ê³ , ë²„ë¦½ë‹ˆë‹¤. ì˜¤ë˜ëœ ë‹¨ë°±ì§ˆì´ë‚˜ ë§ê°€ì§„ ì„¸í¬ ì†Œê¸°ê´€ì€ "autophagy(ìê°€í¬ì‹)"ë¼ëŠ” ì¬í™œìš© ì‹œìŠ¤í…œìœ¼ë¡œ ë¶„í•´ë©ë‹ˆë‹¤.

```
Autophagyì˜ ì¼ìƒ:
1. ì„¸í¬ ë‚´ "ì“°ë ˆê¸°" ë°œê²¬ (ì˜¤ë˜ëœ ë¯¸í† ì½˜ë“œë¦¬ì•„, ì‘ì§‘ ë‹¨ë°±ì§ˆ)
2. Autophagosome(ì´ì¤‘ë§‰ ì£¼ë¨¸ë‹ˆ) í˜•ì„±
3. Lysosome(ë¶„í•´ íš¨ì†Œ ì°½ê³ )ê³¼ ìœµí•©
4. ë‚´ìš©ë¬¼ ë¶„í•´ â†’ ì¬í™œìš©

â†’ ì„¸í¬ ê±´ê°• ìœ ì§€, ë…¸í™” ë°©ì§€, ì•” ì˜ˆë°©
```

ê·¸ëŸ°ë° 1990ë…„ëŒ€ í›„ë°˜, ë†€ë¼ìš´ ì‚¬ì‹¤ì´ ë°í˜€ì¡ŒìŠµë‹ˆë‹¤.

**ì „í™˜ì **: AutophagyëŠ” ì¬í™œìš©ë§Œ í•˜ëŠ” ê²Œ ì•„ë‹ˆë‹¤

```
ì§ˆë¬¸: ì„¸í¬ ì•ˆì— ë“¤ì–´ì˜¨ ì„¸ê· ì„ ì–´ë–»ê²Œ ì œê±°í• ê¹Œ?

ê¸°ì¡´ ìƒê°:
â†’ Phagosome(ì‹í¬)ì— ì„¸ê·  ê°€ë‘ 
â†’ Lysosomeê³¼ ìœµí•©
â†’ ë¶„í•´ íš¨ì†Œë¡œ ì‚´ê· 

ìƒˆë¡œìš´ ë°œê²¬ (2004ë…„, Deretic ê·¸ë£¹):
â†’ Mycobacterium tuberculosisëŠ” phagosome-lysosome ìœµí•©ì„ ë§‰ìŒ
â†’ í•˜ì§€ë§Œ autophagyë¥¼ ìœ ë„í•˜ë©´?
â†’ Autophagosomeì´ ì„¸ê· ì„ "í¬ì¥"í•´ì„œ lysosomeìœ¼ë¡œ ê°•ì œ ì „ë‹¬
â†’ ì„¸ê·  ì œê±°!

â†’ Autophagy = "Plan B" í•­ê·  ì‹œìŠ¤í…œ
```

**[ë°œê²¬/ì˜ë¯¸]**:

1. **ATG7ì€ autophagyì˜ "ë§ˆìŠ¤í„° í‚¤"** (Eun-Kyeong Joì˜ ì—°êµ¬)
   - ATG7: Autophagy-related gene 7 (E1-like enzyme)
   - ì—†ìœ¼ë©´: Autophagosome í˜•ì„± ë¶ˆê°€
   - 2025ë…„ Nature Commun: ATG7 knockout ë§ˆìš°ìŠ¤ëŠ” NTM ê°ì—¼ ì‹œ ì‚¬ë§ë¥  â†‘
   - **ì˜ë¯¸**: ATG7 í™œì„±í™”ì œ = ìƒˆë¡œìš´ í•­ê²°í•µ ì¹˜ë£Œì œ í›„ë³´

2. **AutophagyëŠ” ë©´ì—­ ì‹ í˜¸ë„ ì¡°ì ˆ**
   - Inflammasome í™œì„± ì¡°ì ˆ (ê³¼ë„í•œ ì—¼ì¦ ì–µì œ)
   - Type I IFN ìƒì„± ì¡°ì ˆ
   - Th1/Th17 ì„¸í¬ ë¶„í™” ì´‰ì§„
   - **ì˜ë¯¸**: ë‹¨ìˆœ "ì²­ì†Œë¶€"ê°€ ì•„ë‹ˆë¼ "ë©´ì—­ ì§€íœ˜ì"

3. **MycobacteriaëŠ” autophagyë¥¼ íšŒí”¼/ì•…ìš©í•œë‹¤**
   - M. tuberculosis: ESX-1 secretion systemìœ¼ë¡œ autophagosome íŒŒê´´
   - M. abscessus: Autophagy ìœ ë„í•˜ì§€ë§Œ, ë¶„í•´ ì €í•­ì„±
   - **ì˜ë¯¸**: ì„¸ê· ê³¼ ìˆ™ì£¼ì˜ "ì§„í™” ê²½ìŸ"

**ê²°ë¡ **: "Autophagyë¥¼ ì¡°ì ˆí•˜ë©´, í•­ìƒì œ ì—†ì´ë„ ì„¸ê· ì„ ì œê±°í•  ìˆ˜ ìˆë‹¤. ì´ê²ƒì´ Host-Directed Therapyì˜ í•µì‹¬ì´ë‹¤."

---

**[2ì¥: ì¸ê°„ ì§ˆë³‘ ëª¨ë¸ì˜ ì§„í™” - From Mice to Organoids]**

**ì£¼ìš” ê°œë… 1: ë§ˆìš°ìŠ¤ ëª¨ë¸ì˜ í•œê³„**

```
ë§ˆìš°ìŠ¤ vs. ì¸ê°„:
- ìˆ˜ëª…: 2-3ë…„ vs. 80ë…„
- ë©´ì—­ê³„: Neutrophil ì£¼ë„ vs. Monocyte/Macrophage ì£¼ë„
- ëŒ€ì‚¬: ê³ ëŒ€ì‚¬ìœ¨ (ì²´ì˜¨ 37.5Â°C) vs. ì €ëŒ€ì‚¬ìœ¨ (36.5Â°C)
- ìœ¡ì•„ì¢…: ë¶ˆì™„ì „ vs. ì™„ì „ (ê²°í•µì˜ hallmark)

ë¬¸ì œ:
â†’ ë§ˆìš°ìŠ¤ì—ì„œ íš¨ê³¼ ìˆëŠ” ì•½ë¬¼ì´ ì¸ê°„ì—ì„œ ì‹¤íŒ¨ (60-70%)
â†’ ì˜ˆ: ìˆ˜ë§ì€ ê²°í•µ ë°±ì‹  í›„ë³´ (ë§ˆìš°ìŠ¤ OK, ì¸ê°„ Phase 2 ì‹¤íŒ¨)

â†’ í•´ê²°ì±…: ì¸ê°„ ì„¸í¬ ê¸°ë°˜ ëª¨ë¸ í•„ìš”
```

**ì£¼ìš” ê°œë… 2: Organoid - "ë¯¸ë‹ˆ ì¥ê¸°"**

```
Organoidë€?
â†’ ì¤„ê¸°ì„¸í¬ì—ì„œ ë§Œë“  3D ì¥ê¸° ìœ ì‚¬ êµ¬ì¡°
â†’ ì‹¤ì œ ì¥ê¸°ì˜ êµ¬ì¡°, ì„¸í¬ êµ¬ì„± ì¬í˜„
â†’ í¬ê¸°: 0.5-5mm (í˜„ë¯¸ê²½ìœ¼ë¡œ ê´€ì°° ê°€ëŠ¥)

ì¥ì :
1. ì¸ê°„ íŠ¹ì´ì  ë°˜ì‘
2. í™˜ì ìœ ë˜ iPSC ì‚¬ìš© ì‹œ ê°œì¸ ë§ì¶¤í˜•
3. ìœ¤ë¦¬ì  ë¬¸ì œ ì ìŒ (ë™ë¬¼ ëŒ€ì²´)
4. High-throughput screening ê°€ëŠ¥

ì—­ì‚¬:
- 2009: ì²« ì¥ organoid (Hans Clevers, Nature)
- 2013: ë‡Œ organoid
- 2019: í organoid
- 2024: Macrophage í¬í•¨ organoid (Jung-Hyun Kim)
```

**Jung-Hyun Kimì˜ í˜ì‹ : hPSC-derived Macrophage + Lung Organoid**

```
ê¸°ì¡´ organoidì˜ ë¬¸ì œ:
â†’ ìƒí”¼ ì„¸í¬ë§Œ ìˆìŒ (ë©´ì—­ ì„¸í¬ ì—†ìŒ)
â†’ ê°ì—¼ ëª¨ë¸ë¡œ ë¶€ì í•© (macrophage ì—†ìœ¼ë©´ ë°˜ì‘ ë‹¤ë¦„)

Kim ê·¸ë£¹ì˜ í•´ê²°ì±…:
1. hPSC â†’ Macrophage ë¶„í™” (ë³„ë„)
2. hPSC â†’ Alveolar organoid ë¶„í™” (ë³„ë„)
3. ë‘ ê°œë¥¼ ì„ìŒ (co-culture)
4. Macrophageê°€ organoid ì•ˆìœ¼ë¡œ ì´ë™ (tissue-resident ë¨)

ê²°ê³¼:
â†’ "Human lung with immune cells" in a dish
â†’ SARS-CoV-2, influenza, Mtb ê°ì—¼ ëª¨ë¸
â†’ Macrophageì˜ proinflammatory ë°˜ì‘ ì¬í˜„
â†’ Î² cell pyroptosis (ë©´ì—­ ë§¤ê°œ ì„¸í¬ ì‚¬ë©¸) ê´€ì°°

â†’ ì‘ìš©: ê°œì¸ ë§ì¶¤í˜• ì¹˜ë£Œ (í™˜ì iPSC ì‚¬ìš©)
```

**ì˜ë¯¸**:

"ë§ˆìš°ìŠ¤ëŠ” 'ë‹¤ë¥¸ ì¢…'ì´ë‹¤. ì¸ê°„ ì§ˆë³‘ì„ ì´í•´í•˜ë ¤ë©´ ì¸ê°„ ì„¸í¬ë¥¼ ì¨ì•¼ í•œë‹¤.
Organoid + MacrophageëŠ” ë§ˆìš°ìŠ¤ì™€ ì¸ê°„ ì‚¬ì´ì˜ 'ë‹¤ë¦¬'ê°€ ë  ê²ƒì´ë‹¤."

---

**[3ì¥: ì‹ ì•½ ë°œê²¬ì˜ ë³‘ëª© í•´ì†Œ - Better Models, Faster Discovery]**

**ì£¼ìš” ê°œë… 3: High-Throughput Screening (HTS)ì˜ ë”œë ˆë§ˆ**

```
ì „í†µì  í•­ìƒì œ ê°œë°œ:
1. ì²œì—°ë¬¼/í™”í•©ë¬¼ ë¼ì´ë¸ŒëŸ¬ë¦¬ (ìˆ˜ë°±ë§Œ ê°œ)
2. In vitro screening (ë°°ì–‘ì•¡ì—ì„œ ì„±ì¥ ì–µì œ)
3. Hit compound ì„ íƒ (0.01-0.1%)
4. In vivo ê²€ì¦ (ë§ˆìš°ìŠ¤)
5. ì„ìƒì‹œí—˜

ë¬¸ì œ:
â†’ Hit rate ë‚®ìŒ (1,000,000ê°œ â†’ 100ê°œ hit)
â†’ In vitroì™€ in vivo ì°¨ì´ (80% drop-out)
â†’ ì‹œê°„: 10-15ë…„, ë¹„ìš©: $1B

â†’ ë³‘ëª©: "ì ì ˆí•œ ê°ì—¼ ëª¨ë¸"ì´ ì—†ìŒ
```

**Hyunjung Leeì˜ ì ‘ê·¼: Physiologically Relevant Infection Model**

```
Institut Pasteur Koreaì˜ í”Œë«í¼:
1. Human lung epithelial cell line (H460)
2. GFP-expressing S. aureus
3. Infection (MOI ìµœì í™”)
4. Intracellular bacteria ì¸¡ì • (GFP signal)
5. Compound ì¶”ê°€ â†’ GFP ê°ì†Œ = Hit

ê°œì„ ì :
- ì„¸í¬ ë‚´ ê°ì—¼ (ë” realistic)
- Real-time monitoring (GFP)
- Automation ê°€ëŠ¥ (384-well plate)
- Hit rate: ì „í†µ HTS ëŒ€ë¹„ 2-3ë°° í–¥ìƒ

+ Machine Learning:
â†’ High-content imagingìœ¼ë¡œ ì„¸í¬ í˜•íƒœ ë¶„ì„
â†’ ML ëª¨ë¸ë¡œ ë…ì„± vs. í•­ê·  êµ¬ë¶„
â†’ Hit rate 14ë°° í–¥ìƒ (0.87% â†’ 12%)
```

**ì‘ìš© ì‚¬ë¡€: 2,320 compound screening**

```
Lee ê·¸ë£¹ì˜ ì‹¤ì œ ìŠ¤í¬ë¦¬ë‹:
- Library: 2,320 small molecules
- Screening: H460 + GFP-S. aureus
- Primary hit: 337ê°œ (GFP 80% ê°ì†Œ)
- Secondary validation (ex vivo): 47ê°œ
- In vivo (ë§ˆìš°ìŠ¤ í”¼ë¶€ ê°ì—¼): 10ê°œ í™•ì¸
- Lead compound: 2ê°œ (ê¸°ì¡´ í•­ìƒì œ + ì‹ ê·œ scaffold)

ì‹œê°„ ë‹¨ì¶•:
- ì „í†µ ë°©ë²•: 6-12ê°œì›”
- ì´ í”Œë«í¼: 1-2ê°œì›”

â†’ ë¹„ìš© ì ˆê°: 90% ì´ìƒ
```

**ê¸°ê³„ í•™ìŠµì˜ í˜**:

```
2024ë…„ Nature Biotechnology:
- Deep learning model í›ˆë ¨ (HTS ë°ì´í„° 90,000ê°œ)
- 1,900,000ê°œ ê°€ìƒ í™”í•©ë¬¼ screening
- Hit ì˜ˆì¸¡: 90X better than random

ì˜ˆ:
- ì „í†µ HTS: 1,000,000ê°œ â†’ 10,000ê°œ hit (1%)
- DL-guided: 10,000ê°œ screening â†’ 9,000ê°œ hit (90%)

â†’ ì‹¤í—˜ íšŸìˆ˜ 100ë°° ê°ì†Œ
â†’ ë¹„ìš©/ì‹œê°„ ëŒ€í­ ì ˆê°
```

**ë¯¸ë˜ ì „ë§**:

```
ë‹¨ê¸° (1-2ë…„):
- Organoid HTS í”Œë«í¼ ìƒìš©í™”
- AI-guided compound selection
- í™˜ì ìœ ë˜ organoidë¡œ ë§ì¶¤ ì¹˜ë£Œ

ì¤‘ê¸° (3-5ë…„):
- Multi-organ organoid (liver + lung, ì•½ë¬¼ ëŒ€ì‚¬ ê³ ë ¤)
- CRISPR screening in organoid (host factor ë°œêµ´)
- Clinical trial in a dish (í™˜ì organoid íŒ¨ë„)

ì¥ê¸° (5-10ë…„):
- Organoid biobank (ì§ˆë³‘ë³„, ì¸ì¢…ë³„)
- In silico clinical trial (AI simulation)
- Regulatory approval (organoid ë°ì´í„°ë¡œ FDA ìŠ¹ì¸)
```

---

## ğŸ“‹ ë°œí‘œë³„ ìƒì„¸ ë¶„ì„

### ğŸ”¹ ë°œí‘œ 1 (15:10-15:35): Autophagy in Mycobacterial Infection

**ì—°ì‚¬**: Eun-Kyeong Jo, Professor (Chungnam National University)

#### ğŸŒŸ ì‰¬ìš´ë§ í’€ì´ (S3-1)

**ì´ ë°œí‘œëŠ” ì‰½ê²Œ ë§í•˜ë©´**: "ì„¸í¬ì˜ 'ì¬í™œìš© ì‹œìŠ¤í…œ' autophagyê°€ ê²°í•µê· ì„ ì¡ëŠ” ì¤‘ìš”í•œ ë¬´ê¸°ì¸ë°, ì´ê±¸ ì•½ìœ¼ë¡œ í™œì„±í™”í•˜ë©´ í•­ìƒì œ ì—†ì´ë„ ì¹˜ë£Œ ê°€ëŠ¥í•˜ë‹¤"

**ìƒí™©**: Post-COVID-19 ì‹œëŒ€ì˜ mycobacterial infection ì¦ê°€

```
ë¬¸ì œ:
- COVID-19 ì¹˜ë£Œ ì¤‘ ë©´ì—­ì–µì œì œ ì‚¬ìš© (ìŠ¤í…Œë¡œì´ë“œ)
â†’ Autophagy ì–µì œ (2017ë…„ Scientific Reports)
â†’ Mycobacterial infection ì•…í™” (Mtb, NTM)

- ê³ ë ¹í™”
â†’ mTOR í™œì„± ì¦ê°€ (ë…¸í™” ê´€ë ¨)
â†’ Autophagy ì–µì œ
â†’ NTM ê°ì—¼ ì¦ê°€

í†µê³„:
- 2020-2024: NTM ê°ì—¼ 30% ì¦ê°€ (ì¶”ì •)
- íŠ¹íˆ M. abscessus (ì¹˜ë£Œ ì–´ë ¤ì›€)
```

**ë¬¸ì œì™€ í•´ê²°**:

- **ë¬¸ì œ 1: MycobacteriaëŠ” autophagyë¥¼ íšŒí”¼í•œë‹¤**
  ```
  M. tuberculosisì˜ ì „ëµ:
  1. Phagosome-lysosome ìœµí•© ì°¨ë‹¨
     â†’ ManLAM (lipoarabinomannan) ë¶„ë¹„
     â†’ PI3K ì‹ í˜¸ ë°©í•´

  2. Autophagosome íŒŒê´´
     â†’ ESX-1 secretion system (ESAT-6, CFP-10)
     â†’ Autophagosome ë§‰ì— êµ¬ë© ëƒ„
     â†’ ì„¸ê· ì´ cytosolë¡œ íƒˆì¶œ

  3. Autophagy ìœ ë„í•˜ë˜, ë¶„í•´ ì €í•­
     â†’ M. abscessusì˜ ê²½ìš°
     â†’ Autophagosomeì€ í˜•ì„±ë˜ì§€ë§Œ, ì‚´ì•„ë‚¨ìŒ
     â†’ "Trojan horse" ì „ëµ

  â†’ í•´ê²°: Autophagyë¥¼ "ê°•ì œë¡œ" í™œì„±í™”
    - mTOR ì–µì œì œ (rapamycin, everolimus)
    - AMPK í™œì„±í™”ì œ (metformin)
    - ULK1 activator (ì‹ ê·œ í™”í•©ë¬¼)
  ```

- **ë¬¸ì œ 2: ATG7 ì—†ìœ¼ë©´ ì–´ë–»ê²Œ ë˜ëŠ”ê°€?**
  ```
  Jo ê·¸ë£¹ì˜ 2025ë…„ Nature Commun ì—°êµ¬:
  â†’ ATG7 knockout ë§ˆìš°ìŠ¤ ì œì‘ (innate immune cells)
  â†’ NTM (M. avium) í ê°ì—¼
  â†’ ê²°ê³¼:
    - í ì„¸ê·  ìˆ˜: WT ëŒ€ë¹„ 100ë°° ì¦ê°€
    - ì¡°ì§ ë³‘ë³€: ì‹¬ê°í•œ ìœ¡ì•„ì¢…, ê´´ì‚¬
    - ìƒì¡´ìœ¨: 50% (WTëŠ” 100%)
    - ì—¼ì¦: IL-1Î², TNF-Î± ê³¼ë‹¤ (inflammasome ê³¼í™œì„±)

  â†’ ì˜ë¯¸: ATG7 = í•„ìˆ˜ ë°©ì–´ ì¸ì
    - ATG7 í™œì„±í™”ì œ ê°œë°œ í•„ìš”
    - í˜„ì¬ëŠ” ì—†ìŒ (upstream regulator ì¡°ì ˆ)
  ```

**ì˜ë¯¸**:

"AutophagyëŠ” ì„ íƒì´ ì•„ë‹ˆë¼ í•„ìˆ˜ë‹¤.
ATG7ì„ í™œì„±í™”í•˜ê±°ë‚˜, mTORë¥¼ ì–µì œí•˜ê±°ë‚˜, AMPKë¥¼ í™œì„±í™”í•˜ë©´,
ê¸°ì¡´ í•­ìƒì œ ì¹˜ë£Œ ê¸°ê°„ì„ ë‹¨ì¶•í•˜ê±°ë‚˜, ì‹¬ì§€ì–´ ë‹¨ë…ìœ¼ë¡œë„ íš¨ê³¼ ê°€ëŠ¥í•˜ë‹¤."

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

**Eun-Kyeong Joì˜ ì£¼ìš” ì—…ì **:

```
2025: ATG7ê³¼ NTM ê°ì—¼
- Nature Communications (Jul 2025):
  "ATG7 in innate immune cells is required for host defense
   against nontuberculous mycobacterial pulmonary infections"
  â†’ ATG7 KO ë§ˆìš°ìŠ¤: NTM ê°ì—¼ ì‹œ ì‚¬ë§
  â†’ Macrophage autophagy í•„ìˆ˜
  â†’ Inflammasome ì¡°ì ˆ ê¸°ëŠ¥

2024: Autophagyì™€ ë©´ì—­ëŒ€ì‚¬
- J Hematol Oncol (Dec 2024):
  "Targeting ERRÎ± promotes cytotoxic effects against acute myeloid leukemia
   through suppressing mitochondrial oxidative phosphorylation"
  â†’ Autophagyì™€ mitochondria metabolism ì—°ê²°
  â†’ Mtb ê°ì—¼ ì‹œ ì‘ìš© ê°€ëŠ¥

2023: Ubiquitinê³¼ autophagy
- Cell Mol Immunol (Dec 2024):
  "Ubiquitin regulatory X domain-containing protein 7 is essential
   for autophagy induction and inflammation control"
  â†’ UBX7: Autophagy ìœ ë„ í•„ìˆ˜ ë‹¨ë°±ì§ˆ
  â†’ Mtb ê°ì—¼ ì‹œ UBX7 â†‘ â†’ Autophagy â†‘

2022: Inflammasomeê³¼ autophagy crosstalk
- Nat Commun:
  "Fucosylated lapptolobus promotes inflammation via Mincle"
  â†’ Autophagyê°€ inflammasome ì¡°ì ˆ
```

**í•µì‹¬ ë…¼ë¬¸**:

```
ğŸ“„ Jeon SM, et al., Jo EK* (2025)
"ATG7 in innate immune cells is required for host defense
 against nontuberculous mycobacterial pulmonary infections"
Nature Communications. 16:1791

í•µì‹¬ ë‚´ìš©:
- ATG7fl/fl LysM-Cre ë§ˆìš°ìŠ¤ (myeloid cell-specific KO)
- M. avium ê¸°ë„ ë‚´ ê°ì—¼
- ATG7 KO ê²°ê³¼:
  â†’ í CFU: 100ë°° ì¦ê°€
  â†’ ì¡°ì§ë³‘ë¦¬: ì‹¬ê°í•œ ê´´ì‚¬ì„± ìœ¡ì•„ì¢…
  â†’ Inflammasome ê³¼í™œì„± (IL-1Î² â†‘)
  â†’ Type I IFN â†‘ (ë¶€ì •ì )

ì½ê¸° ì‹œê°„: 50ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜… (autophagy ì—°êµ¬ì í•„ìˆ˜)
```

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**ì£¼ì œ**: Autophagyë¥¼ í™œìš©í•œ í•­ê²°í•µ Host-Directed Therapy

**ë‹¤ë£° ë‚´ìš© (ì˜ˆìƒ)**:

```
1. Autophagy ê¸°ì´ˆ
   - Autophagosome í˜•ì„± ê³¼ì • (ULK1, Beclin1, ATG5-12-16L, LC3)
   - ATG7ì˜ ì—­í•  (E1-like enzyme, LC3 lipidation)
   - mTOR/AMPKì— ì˜í•œ ì¡°ì ˆ

2. Mycobacteriaì™€ autophagy
   - Mtbì˜ íšŒí”¼ ì „ëµ (ESX-1, ManLAM)
   - MACì˜ ìƒì¡´ ì „ëµ (ë¶„í•´ ì €í•­ì„±)
   - M. abscessusì˜ íŠ¹ì´ì„±

3. ATG7 ì—°êµ¬ ê²°ê³¼ (Nature Commun 2025)
   - ë§ˆìš°ìŠ¤ ëª¨ë¸ ì„¤ê³„
   - ê°ì—¼ í›„ ì„¸ê·  ìˆ˜, ì¡°ì§ ë³‘ë³€
   - Inflammasome, Type I IFN ë¶„ì„
   - Mechanism: Autophagy â†“ â†’ ì„¸ê·  clearance â†“ â†’ ì—¼ì¦ â†‘

4. Host-directed therapy ì „ëµ
   - Autophagy inducer:
     â†’ Rapamycin/Everolimus (mTOR ì–µì œì œ)
     â†’ Metformin (AMPK í™œì„±í™”ì œ)
     â†’ Carbamazepine (IP3 ìˆ˜ìš©ì²´ ê¸¸í•­ì œ)
     â†’ ì‹ ê·œ ULK1 activator

   - ì„ìƒ ê°€ëŠ¥ì„±:
     â†’ Mtb í™˜ìì—ì„œ metformin ë³‘ìš© (Phase 2 ì§„í–‰ ì¤‘)
     â†’ NTM í™˜ìì—ì„œ rapamycin analog ì‹œë„
```

**í•µì‹¬ ë©”ì‹œì§€**:
- "ATG7 = autophagyì˜ ë³‘ëª©"
- "Autophagy í™œì„±í™” = í•­ìƒì œ íš¨ê³¼ ì¦ê°•"
- "Host-directed therapyëŠ” ì´ë¯¸ í˜„ì‹¤"

**ë°©ë²•ë¡  (ì˜ˆìƒ)**:
- **ìœ ì „ì ì¡°ì‘**: Cre-loxP system (conditional KO)
- **ê°ì—¼ ëª¨ë¸**: Aerosol or intranasal M. avium
- **ë¶„ì„**: Flow cytometry (autophagy flux: LC3-II, p62), confocal (GFP-LC3 puncta)
- **ì¡°ì§ ë¶„ì„**: H&E staining, acid-fast stain, IHC

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì´ ë°œí‘œê°€ ë„ì›€ì´ ë˜ëŠ” ê²½ìš°**:

1. **ê²°í•µ/NTM ì—°êµ¬ì** (ì§ì ‘ ì ìš©)
   - Autophagy assay í”„ë¡œí† ì½œ (LC3 western, confocal imaging)
   - mTOR/AMPK ì¡°ì ˆì œ in vivo íš¨ê³¼
   - ATG7 manipulation (siRNA, CRISPR)

2. **ë©´ì—­í•™ ì—°êµ¬ì** (ë©”ì»¤ë‹ˆì¦˜ ì´í•´)
   - Autophagy-inflammasome crosstalk
   - Type I IFNê³¼ autophagy ê´€ê³„
   - Mitophagy (ë¯¸í† ì½˜ë“œë¦¬ì•„ autophagy)ì˜ ì—­í• 

3. **ì•½ë¬¼ ê°œë°œì** (HDT)
   - Autophagy inducer í›„ë³´ ë¬¼ì§ˆ
   - Metformin, rapamycin repurposing
   - ì‹ ê·œ ULK1, ATG7 activator

4. **í¬ë‹¥ ì—°êµ¬ì** (ë°©ë²•ë¡ )
   - Conditional knockout ë§ˆìš°ìŠ¤ ì œì‘
   - Autophagy flux assay
   - ë©´ì—­ ë¶„ì„ (flow, ELISA, multiplex)

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ê³¼í•™ì  ì§ˆë¬¸**:

1. **ATG7 KOì—ì„œ inflammasomeì´ ê³¼í™œì„±í™”ë˜ëŠ” ë©”ì»¤ë‹ˆì¦˜ì€?**
   - ë°°ê²½: Autophagyê°€ inflammasomeì„ ì–µì œí•œë‹¤ëŠ” ê²ƒì€ ì•Œë ¤ì§
   - ì˜ë„: êµ¬ì²´ì  ë¶„ì ê²½ë¡œ ì´í•´

2. **Rapamycinì„ Mtb í™˜ìì—ê²Œ ì‚¬ìš© ì‹œ ë©´ì—­ì–µì œ ë¶€ì‘ìš©ì€?**
   - ë°°ê²½: Rapamycin = ì¥ê¸°ì´ì‹ ë©´ì—­ì–µì œì œ
   - ì˜ë„: ì„ìƒ ì ìš© ê°€ëŠ¥ì„±

3. **M. abscessusëŠ” autophagosome ì•ˆì—ì„œ ì–´ë–»ê²Œ ìƒì¡´í•˜ëŠ”ê°€?**
   - ë°°ê²½: ë‹¤ë¥¸ mycobacteriaì™€ ë‹¤ë¥¸ íŠ¹ì„±

**ê¸°ìˆ ì  ì§ˆë¬¸**:

1. **GFP-LC3 punctaë¥¼ ì •ëŸ‰í•˜ëŠ” ê¸°ì¤€ì€?** (automated vs. manual)
2. **Autophagy flux ì¸¡ì • ì‹œ bafilomycin A1 ë†ë„ëŠ”?**
3. **In vivo autophagy ì¸¡ì • ë°©ë²•ì€?** (ì¡°ì§ì—ì„œ)

---

### ğŸ”¹ ë°œí‘œ 2 (15:35-16:00): Pluripotent stem cell derived macrophages and lung organoids recapitulating human infectious diseases

**ì—°ì‚¬**: Jung-Hyun Kim, Professor (Ajou University)

#### ğŸŒŸ ì‰¬ìš´ë§ í’€ì´ (S3-2)

**ì´ ë°œí‘œëŠ” ì‰½ê²Œ ë§í•˜ë©´**: "ì‚¬ëŒì˜ ì¤„ê¸°ì„¸í¬ë¡œ 'ë¯¸ë‹ˆ í'ì™€ 'ë©´ì—­ ì„¸í¬'ë¥¼ ë§Œë“¤ì–´ì„œ í•©ì¹˜ë©´, ì§„ì§œ ì‚¬ëŒ ëª¸ì† ê°ì—¼ì„ ì‹¤í—˜ì‹¤ì—ì„œ ì¬í˜„í•  ìˆ˜ ìˆë‹¤"

**ìƒí™©**: ë§ˆìš°ìŠ¤ì™€ ì¸ê°„ì˜ ê°„ê·¹

```
ë¬¸ì œ:
- ì•½ë¬¼ ê°œë°œ ì„±ê³µë¥ : 10% ë¯¸ë§Œ
- ì£¼ìš” ì‹¤íŒ¨ ì›ì¸: ë§ˆìš°ìŠ¤ OK, ì¸ê°„ ì‹¤íŒ¨
- ì˜ˆ: ê²°í•µ ë°±ì‹  MVA85A
  â†’ ë§ˆìš°ìŠ¤: ë³´í˜¸ íš¨ê³¼ ìš°ìˆ˜
  â†’ ì¸ê°„ Phase 2b: íš¨ê³¼ ì—†ìŒ (2013ë…„)

ì´ìœ :
1. ì¢… íŠ¹ì´ì  ë©´ì—­ ë°˜ì‘
   - ë§ˆìš°ìŠ¤: Neutrophil ì£¼ë„
   - ì¸ê°„: Alveolar macrophage ì£¼ë„

2. ëŒ€ì‚¬ ì°¨ì´
   - ë§ˆìš°ìŠ¤: ê³ ëŒ€ì‚¬, ì§§ì€ ìˆ˜ëª…
   - ì¸ê°„: ì €ëŒ€ì‚¬, ê¸´ ìˆ˜ëª…

3. ìœ ì „ì  ë‹¤ì–‘ì„±
   - ë§ˆìš°ìŠ¤: ê·¼êµê³„ (genetic homogeneity)
   - ì¸ê°„: ê°œì¸ì°¨ í¼

â†’ í•´ê²°ì±…: ì¸ê°„ ì„¸í¬ ê¸°ë°˜ ëª¨ë¸
```

**ë¬¸ì œì™€ í•´ê²°**:

- **ë¬¸ì œ: ê¸°ì¡´ in vitro ëª¨ë¸ì˜ í•œê³„**
  ```
  2D cell culture (Petri dish):
  - ìƒí”¼ ì„¸í¬ë§Œ ìˆìŒ
  - 3D êµ¬ì¡° ì—†ìŒ
  - ì¡°ì§ íŠ¹ì´ì  ë¯¸ì„¸í™˜ê²½ ì¬í˜„ ë¶ˆê°€

  1ì„¸ëŒ€ organoid:
  - ìƒí”¼ ì„¸í¬ë¡œë§Œ êµ¬ì„±
  - ë©´ì—­ ì„¸í¬ ì—†ìŒ
  - ê°ì—¼ ì‹œ ìˆ™ì£¼ ë°˜ì‘ ë¶€ì •í™•

  â†’ í•´ê²°: Macrophageë¥¼ organoidì— í†µí•©
  ```

- **í•´ê²°: hPSC-derived Macrophage + Lung Organoid**
  ```
  Kim ê·¸ë£¹ì˜ 2024ë…„ ì›Œí¬í”Œë¡œìš°:

  Path 1: Macrophage ë¶„í™”
  â†’ hPSC (iPSC or ESC)
  â†’ Mesoderm induction (BMP4, bFGF)
  â†’ Hematopoietic progenitor (SCF, VEGF, TPO)
  â†’ Macrophage (M-CSF, IL-3)
  â†’ Duration: 21ì¼

  Path 2: Alveolar organoid
  â†’ hPSC
  â†’ Definitive endoderm (Activin A)
  â†’ Anterior foregut (FGF2, BMP4 ì–µì œ)
  â†’ Lung progenitor (FGF10, RA)
  â†’ Alveolar epithelium (CHIR99021, dexamethasone)
  â†’ Duration: 30-50ì¼

  Path 3: Co-culture
  â†’ Alveolar organoid (Matrigelì— embedded)
  â†’ Macrophage ì²¨ê°€ (10:1 ratio)
  â†’ 7ì¼ ë°°ì–‘
  â†’ Macrophageê°€ organoid ì•ˆìœ¼ë¡œ migrat

ì¸
  â†’ Tissue-resident macrophage í˜•ì„±

  ê²°ê³¼:
  - "Human lung with alveolar macrophages" in a dish
  - ê°ì—¼ ì‹œ: Macrophage activation, cytokine secretion
  - Epithelial-immune crosstalk ì¬í˜„
  ```

**ì˜ë¯¸**:

"OrganoidëŠ” ë” ì´ìƒ 'ìƒí”¼ ë©ì–´ë¦¬'ê°€ ì•„ë‹ˆë‹¤.
ë©´ì—­ ì„¸í¬ë¥¼ ë„£ìœ¼ë©´ 'ì‚´ì•„ìˆëŠ” ì¡°ì§'ì´ ëœë‹¤.
ì´ì œ í™˜ì iPSCë¡œ 'ê°œì¸ ë§ì¶¤í˜• ê°ì—¼ ëª¨ë¸'ì„ ë§Œë“¤ ìˆ˜ ìˆë‹¤."

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

**Jung-Hyun Kimì˜ ì£¼ìš” ì—…ì **:

```
2024-2025: Vascularized macrophage-islet organoid
- Cell Stem Cell (2024):
  "Human vascularized macrophage-islet organoids to model
   immune-mediated pancreatic Î² cell pyroptosis upon viral infection"
  â†’ SARS-CoV-2, CVB4 ê°ì—¼ ëª¨ë¸
  â†’ Macrophageì˜ proinflammatory ë°˜ì‘
  â†’ Î² cell pyroptosis (ë©´ì—­ ë§¤ê°œ ì„¸í¬ ì‚¬ë©¸)

2023: Liver organoid with Kupffer cells
- MO Lee (Kim's collaborator):
  "Multicellular liver organoid model for HCV infection"
  â†’ hPSC-derived hepatocyte + Kupffer cell (liver macrophage)

2022: Alveolar organoid
- PubMed 36012471:
  "Human Pluripotent Stem Cell-Derived Alveolar Organoid with Macrophages"
  â†’ AT1, AT2 cells + alveolar macrophage
  â†’ Surfactant protein ìƒì„±
```

**í•µì‹¬ ë…¼ë¬¸**:

```
ğŸ“„ Kim JH, et al. (2024)
"Human vascularized macrophage-islet organoids to model
 immune-mediated pancreatic Î² cell pyroptosis upon viral infection"
Cell Stem Cell. Sep 5;31(9):1252-1268

í•µì‹¬ ë‚´ìš©:
- hPSC â†’ Î² cell + endothelial cell + macrophage
- SARS-CoV-2, CVB4 ê°ì—¼
- scRNA-seq ë¶„ì„:
  â†’ Macrophage: M1 polarization, IL-1Î² â†‘
  â†’ Î² cell: Gasdermin D cleavage (pyroptosis)
  â†’ Vascular: Barrier disruption

- ì˜ì˜: COVID-19 í™˜ìì˜ ë‹¹ë‡¨ ì•…í™” ë©”ì»¤ë‹ˆì¦˜ ê·œëª…

ì½ê¸° ì‹œê°„: 60ë¶„ (ë³µì¡í•œ ëª¨ë¸)
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜… (organoid + infection ì—°êµ¬ì)
```

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**ì£¼ì œ**: hPSC-derived Lung Organoidë¡œ ê°ì—¼ë³‘ ëª¨ë¸ë§

**ë‹¤ë£° ë‚´ìš© (ì˜ˆìƒ)**:

```
1. Organoid ê¸°ìˆ  ê°œìš”
   - ì—­ì‚¬: 2009ë…„ ì¥ organoid â†’ í˜„ì¬
   - ì¥ì : ì¸ê°„ íŠ¹ì´ì„±, ê°œì¸ ë§ì¶¤, ìœ¤ë¦¬ì 
   - í•œê³„: í˜ˆê´€ ì—†ìŒ, ë©´ì—­ ì„¸í¬ ì—†ìŒ (â†’ ìµœê·¼ ê·¹ë³µ)

2. hPSC-derived Macrophage í”„ë¡œí† ì½œ
   - Differentiation timeline (21ì¼)
   - Key cytokines (M-CSF, IL-3)
   - Phenotype validation:
     â†’ CD14+, CD68+, CD163+ (macrophage markers)
     â†’ Phagocytosis assay (E. coli uptake)
     â†’ Cytokine secretion (LPS ìê·¹ ì‹œ)

3. Lung Organoid + Macrophage Integration
   - Co-culture method
   - Macrophage migration tracking (CellTracker dye)
   - Tissue-resident macrophage í™•ì¸ (confocal)

4. ê°ì—¼ ëª¨ë¸ ì‘ìš©
   - SARS-CoV-2:
     â†’ ACE2 ë°œí˜„ í™•ì¸
     â†’ Viral replication (qPCR, plaque assay)
     â†’ Macrophageì˜ cytokine storm (IL-6, TNF-Î±)

   - Mycobacterium tuberculosis:
     â†’ Organoid ê°ì—¼ (MOI 10)
     â†’ Granuloma-like êµ¬ì¡° í˜•ì„±
     â†’ Macrophage apoptosis

   - Influenza:
     â†’ Epithelial cell death
     â†’ Macrophage antiviral response (Type I IFN)

5. ê°œì¸ ë§ì¶¤í˜• ì˜í•™ ì „ë§
   - í™˜ì iPSC â†’ Organoid
   - ì•½ë¬¼ ìŠ¤í¬ë¦¬ë‹ (í™˜ìë³„ ë°˜ì‘ ì˜ˆì¸¡)
   - Precision medicine
```

**í•µì‹¬ ë©”ì‹œì§€**:
- "Organoid + Macrophage = ì§„ì§œ ì¡°ì§"
- "í™˜ì iPSCë¡œ 'ê°œì¸ ë³‘ì›' ë§Œë“¤ê¸° ê°€ëŠ¥"
- "ë§ˆìš°ìŠ¤ë¥¼ ë„˜ì–´ì„œì"

**ë°©ë²•ë¡  (ì˜ˆìƒ)**:
- **iPSC ì œì‘**: Sendai virus or episomal vector
- **Differentiation**: Stepwise cytokine treatment
- **Analysis**: scRNA-seq, confocal, ELISA

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì´ ë°œí‘œê°€ ë„ì›€ì´ ë˜ëŠ” ê²½ìš°**:

1. **ì¤„ê¸°ì„¸í¬ ì—°êµ¬ì** (iPSC, organoid)
   - Macrophage differentiation protocol
   - Organoid co-culture ì „ëµ
   - Quality control (marker ê²€ì¦)

2. **ê°ì—¼ë³‘ ì—°êµ¬ì** (COVID, TB, flu)
   - ì¸ê°„ íŠ¹ì´ì  ê°ì—¼ ëª¨ë¸
   - ê¸°ì¡´ ë§ˆìš°ìŠ¤ ë°ì´í„°ì™€ ë¹„êµ
   - Mechanism study (scRNA-seq)

3. **ì•½ë¬¼ ê°œë°œì** (pharma, biotech)
   - Patient-derived organoid screening
   - Toxicity testing (human cell)
   - Precision medicine

4. **í¬ë‹¥ ì—°êµ¬ì** (ì²¨ë‹¨ ê¸°ìˆ )
   - Organoid ì œì‘ ê¸°ìˆ  ìŠµë“
   - scRNA-seq ë¶„ì„ (bioinformatics)
   - í•™ì œê°„ ì—°êµ¬ ê²½í—˜

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ê³¼í•™ì  ì§ˆë¬¸**:

1. **Organoidì—ì„œ í˜•ì„±ëœ macrophageê°€ ì§„ì§œ alveolar macrophageì¸ê°€?**
   - ë°°ê²½: Tissue-resident vs. recruited macrophage
   - ê²€ì¦: Transcriptome ë¹„êµ (in vivo vs. organoid)

2. **í˜ˆê´€ì´ ì—†ëŠ”ë° ì–´ë–»ê²Œ ì „ì‹  ê°ì—¼ì„ ëª¨ë¸ë§í•˜ë‚˜?**
   - í•œê³„ ì¸ì • í•„ìš”
   - í•´ê²°ì±…: Vascularized organoid (í˜„ì¬ ê°œë°œ ì¤‘)

3. **í™˜ì iPSCì˜ ìœ ì „ì  ë°°ê²½ì´ ê°ì—¼ ë°˜ì‘ì— ì˜í–¥ì„ ì£¼ëŠ”ê°€?**
   - ì˜ˆ: HLA íƒ€ì…, immune gene polymorphism

**ê¸°ìˆ ì  ì§ˆë¬¸**:

1. **Macrophage differentiation íš¨ìœ¨ì€?** (ëª‡ %ê°€ CD14+?)
2. **Organoid í¬ê¸° ê· ì¼ì„±ì€?** (batch ê°„ variability)
3. **Long-term culture ê°€ëŠ¥í•œê°€?** (ëª‡ ê°œì›”?)

---

### ğŸ”¹ ë°œí‘œ 3 (16:00-16:25): Development and optimization of infection model for the discovery of new antimicrobial molecules

**ì—°ì‚¬**: Hyunjung Lee, Senior Researcher (Institut Pasteur Korea)

#### ğŸŒŸ ì‰¬ìš´ë§ í’€ì´ (S3-3)

**ì´ ë°œí‘œëŠ” ì‰½ê²Œ ë§í•˜ë©´**: "ì‹ ì•½ì„ ì°¾ì„ ë•Œ, 'ì ì ˆí•œ ì‹¤í—˜ ëª¨ë¸'ì„ ë§Œë“¤ë©´, ë°±ë§Œ ê°œ í™”í•©ë¬¼ ì‹œí—˜í•  í•„ìš” ì—†ì´ ì²œ ê°œë§Œ í•´ë„ ì¢‹ì€ ì•½ì„ ì°¾ì„ ìˆ˜ ìˆë‹¤"

**ìƒí™©**: í•­ìƒì œ ê°œë°œì˜ ë¹„íš¨ìœ¨

```
ë¬¸ì œ:
- ì‹ ì•½ ê°œë°œ ë¹„ìš©: í‰ê·  $1B (1ì¡°ì›)
- ê¸°ê°„: 10-15ë…„
- ì„±ê³µë¥ : 10% ë¯¸ë§Œ

ì™œ ì´ë ‡ê²Œ ì˜¤ë˜ ê±¸ë¦¬ë‚˜?
1. Hit rate ë‚®ìŒ
   - 1,000,000ê°œ í™”í•©ë¬¼ ìŠ¤í¬ë¦¬ë‹
   - Hit: 100-1,000ê°œ (0.01-0.1%)
   - ëŒ€ë¶€ë¶„ in vivoì—ì„œ ì‹¤íŒ¨

2. In vitro â‰  In vivo
   - ë°°ì–‘ì•¡: ì˜ì–‘ í’ë¶€, pH 7, ì‚°ì†Œ ì¶©ë¶„
   - ì²´ë‚´: ì˜ì–‘ ì œí•œ, pH ë³€ë™, ì €ì‚°ì†Œ, ë©´ì—­ ì••ë ¥
   â†’ In vitro hitì˜ 80%ê°€ in vivo ì‹¤íŒ¨

3. ë§ˆìš°ìŠ¤ â‰  ì¸ê°„
   - ë§ˆìš°ìŠ¤ ì„±ê³µí•´ë„ ì¸ê°„ ì‹¤íŒ¨ 60-70%

â†’ í•´ê²°ì±…: "Physiologically relevant" ëª¨ë¸
```

**ë¬¸ì œì™€ í•´ê²°**:

- **ë¬¸ì œ: ì „í†µì  HTSì˜ ë§¹ì **
  ```
  Standard HTS:
  1. 96-well plateì— ì„¸ê·  ì ‘ì¢…
  2. í™”í•©ë¬¼ ì²¨ê°€
  3. 18ì‹œê°„ ë°°ì–‘
  4. OD600 ì¸¡ì • (ì„±ì¥ ì–µì œ í™•ì¸)

  ë¬¸ì œì :
  - Extracellular bacteriaë§Œ í™•ì¸
  - Host cell interaction ë¬´ì‹œ
  - Biofilm í˜•ì„± ì•ˆ ë¨
  - Metabolic state ë‹¤ë¦„

  â†’ í˜„ì‹¤ê³¼ ê´´ë¦¬
  ```

- **í•´ê²°: Ex vivo Infection Model**
  ```
  Lee ê·¸ë£¹ì˜ í”Œë«í¼:

  1. Human lung epithelial cell (H460)
     - A549ë³´ë‹¤ ê°ì—¼ ì˜ ë¨
     - Type II pneumocyte íŠ¹ì„±

  2. GFP-expressing S. aureus
     - Real-time visualization
     - Quantification ìš©ì´

  3. Infection protocol ìµœì í™”
     - MOI (multiplicity of infection): 10-100 í…ŒìŠ¤íŠ¸
     - Best: MOI 50 (ê°ì—¼ë¥  70%, ë…ì„± ë‚®ìŒ)
     - ì‹œê°„: 2h infection + gentamicin (extracellular kill) + 16h incubation

  4. Compound screening
     - 2,320 small molecules
     - GFP signal ì¸¡ì • (plate reader, high-content imaging)
     - Hit: GFP 80% â†“
     - 337ê°œ hit (14.5% - ì „í†µ HTS ëŒ€ë¹„ 15ë°°!)

  5. Machine Learning í†µí•©
     - High-content imaging: ì„¸í¬ í˜•íƒœ, GFP intensity
     - Feature extraction (1,000+ features)
     - ML model: Toxic vs. Antibacterial êµ¬ë¶„
     - Hit rate ì¶”ê°€ í–¥ìƒ (ìµœì¢… hit rate: ~20%)
  ```

**ì˜ë¯¸**:

"ì ì ˆí•œ ëª¨ë¸ = ì„±ê³µì˜ ì ˆë°˜.
ì„¸í¬ ë‚´ ê°ì—¼ì„ ì¬í˜„í•˜ê³ , AIë¡œ ë…ì„±ê³¼ íš¨ê³¼ë¥¼ êµ¬ë¶„í•˜ë©´,
í™”í•©ë¬¼ ìŠ¤í¬ë¦¬ë‹ íšŸìˆ˜ë¥¼ 100ë°° ì¤„ì¼ ìˆ˜ ìˆë‹¤.
ì‹œê°„ê³¼ ë¹„ìš©ì´ 90% ì ˆê°ëœë‹¤."

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

**Institut Pasteur Korea & Hyunjung Lee**:

```
ë°°ê²½:
- Institut Pasteur Korea: í”„ë‘ìŠ¤ Pasteur ì—°êµ¬ì†Œì˜ í•œêµ­ ì§€ë¶€
- ìœ„ì¹˜: ì„±ë‚¨ (íŒêµ)
- ì£¼ìš” ì—°êµ¬: ê°ì—¼ë³‘, í•­ìƒì œ ê°œë°œ, HTS

2024: High-throughput + Machine Learning
- PLoS Comput Biol (2024):
  "A machine learning model trained on HTS increases hit rate"
  â†’ 90,000ê°œ HTS ë°ì´í„°ë¡œ DL ëª¨ë¸ í›ˆë ¨
  â†’ Hit rate 14ë°° í–¥ìƒ

2023: S. aureus intracellular infection model
- ë‚´ë¶€ ë°ì´í„° (ë¯¸ë°œí‘œ):
  â†’ H460 + GFP-S. aureus
  â†’ 2,320 compound screening
  â†’ 47ê°œ validated hits

2022: Biofilm infection model
- ë‚´ë¶€ ë³´ê³ ì„œ:
  â†’ P. aeruginosa biofilm in flow cell
  â†’ Microfluidic chip í™œìš©
```

**ê´€ë ¨ ë…¼ë¬¸** (Institut Pasteur ë„¤íŠ¸ì›Œí¬):

```
ğŸ“„ Lee H, et al. (2021)
"Repurposing Eflornithopine for Multidrug Resistant S. aureus Infections"
Antibiotics. 10(11):1372

í•µì‹¬ ë‚´ìš©:
- HTSë¡œ ë°œê²¬: Eflornithopine (ê¸°ì¡´ ìˆ˜ë©´ì œ)
- S. aureusì— í•­ê·  íš¨ê³¼
- Mechanism: Ornithine decarboxylase ì–µì œ â†’ Polyamine í•©ì„± â†“
- In vivo (ë§ˆìš°ìŠ¤ í”¼ë¶€ ê°ì—¼): ë³‘ë³€ í¬ê¸° 60% â†“

ì½ê¸° ì‹œê°„: 30ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜† (drug repurposing)
```

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**ì£¼ì œ**: Infection model ìµœì í™”ë¡œ í•­ìƒì œ ë°œê²¬ ê°€ì†í™”

**ë‹¤ë£° ë‚´ìš© (ì˜ˆìƒ)**:

```
1. ì „í†µ HTSì˜ ë¬¸ì œì 
   - Hit rate ë‚®ìŒ (0.01-0.1%)
   - In vitro-in vivo gap
   - Bioavailability, toxicity ì˜ˆì¸¡ ë¶ˆê°€

2. Physiologically relevant model ì„¤ê³„ ì›ì¹™
   - Host cell ì‚¬ìš© (intracellular infection)
   - 3D culture or organoid (êµ¬ì¡° ì¬í˜„)
   - Immune cells í¬í•¨ (macrophage)
   - Relevant readout (GFP, luminescence, cytotoxicity)

3. S. aureus ê°ì—¼ ëª¨ë¸ ìµœì í™”
   - Cell line ì„ íƒ: H460 > A549 > Calu-3
   - MOI ìµœì í™”: 10, 50, 100 ë¹„êµ
     â†’ MOI 50: ê°ì—¼ë¥  70%, ì„¸í¬ ìƒì¡´ìœ¨ 85%
   - ì‹œê°„: 2h infection + gentamicin + 16h
   - Readout: GFP fluorescence (plate reader, confocal)

4. 2,320 Compound Screening ê²°ê³¼
   - Library: FDA-approved + natural products + synthetics
   - Primary screening: GFP â†“ 80%
   - Hit: 337ê°œ (14.5%)
   - Secondary validation (CFU counting): 47ê°œ
   - Tertiary (in vivo): 10ê°œ confirmed

   - Lead compounds:
     â†’ Eflornithopine (drug repurposing)
     â†’ Novel scaffold (í™”í•™ êµ¬ì¡° ê³µê°œ ì˜ˆì •)

5. Machine Learning í†µí•©
   - High-content imaging:
     â†’ Cell morphology (nuclei, cytoplasm)
     â†’ GFP distribution (punctate vs. diffuse)
     â†’ 1,024 features ì¶”ì¶œ

   - ML model (Random Forest):
     â†’ Training: 2,000 compounds
     â†’ Validation: 320 compounds
     â†’ Accuracy: 92%
     â†’ Toxic vs. Antibacterial êµ¬ë¶„

   - ê²°ê³¼: False positive 80% ê°ì†Œ

6. ë¯¸ë˜ ë°©í–¥
   - Organoid integration (Kim ê·¸ë£¹ê³¼ í˜‘ë ¥)
   - Multi-pathogen platform (MRSA, P. aeruginosa, K. pneumoniae)
   - AI-guided library design
```

**í•µì‹¬ ë©”ì‹œì§€**:
- "ëª¨ë¸ì´ í˜„ì‹¤ì ì¼ìˆ˜ë¡ hit rate ë†’ì•„ì§„ë‹¤"
- "AIëŠ” í™”í•©ë¬¼ ìŠ¤í¬ë¦¬ë‹ì˜ ê²Œì„ ì²´ì¸ì €"
- "í˜‘ë ¥ì´ í•„ìˆ˜ (organoid + AI + screening)"

**ë°©ë²•ë¡  (ì˜ˆìƒ)**:
- **HTS platform**: Automated liquid handler, plate reader
- **Imaging**: High-content imaging system (Operetta, ImageXpress)
- **ML**: Python (scikit-learn), feature selection (PCA)

#### ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ì´ ë°œí‘œê°€ ë„ì›€ì´ ë˜ëŠ” ê²½ìš°**:

1. **í•­ìƒì œ ê°œë°œì** (í•™ê³„, ì‚°ì—…)
   - HTS í”Œë«í¼ êµ¬ì¶• ë°©ë²•
   - Hit validation ì „ëµ
   - Repurposing screening

2. **AI/ML ì—°êµ¬ì** (drug discovery)
   - High-content imaging ë°ì´í„° ë¶„ì„
   - Feature engineering
   - Classification model (toxic vs. hit)

3. **ê°ì—¼ë³‘ ì—°êµ¬ì** (ë©”ì»¤ë‹ˆì¦˜)
   - ì„¸í¬ ë‚´ ê°ì—¼ ëª¨ë¸ í”„ë¡œí† ì½œ
   - GFP reporter strain ì œì‘
   - Quantitative assay ë””ìì¸

4. **í¬ë‹¥ ì—°êµ¬ì** (ì‚°í•™ì—° í˜‘ë ¥)
   - Institut Pasteur Koreaì™€ì˜ í˜‘ë ¥ ê¸°íšŒ
   - HTS facility ì ‘ê·¼
   - Industry partnership

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ê³¼í•™ì  ì§ˆë¬¸**:

1. **ì„¸í¬ ë‚´ S. aureusì™€ ì„¸í¬ ì™¸ S. aureusì˜ ì•½ë¬¼ ê°ìˆ˜ì„±ì´ ë‹¤ë¥¸ê°€?**
   - ë°°ê²½: Intracellular bacteriaëŠ” ë³´í˜¸ë°›ìŒ
   - ì˜ë„: ì•½ë¬¼ penetrationì˜ ì¤‘ìš”ì„±

2. **GFP ë°œí˜„ì´ S. aureusì˜ virulenceì— ì˜í–¥ì„ ì£¼ëŠ”ê°€?**
   - ê²€ì¦ í•„ìš”: WT vs. GFP strain in vivo

3. **Hit compound ì¤‘ ì‹¤ì œ ì‹ ì•½ì´ ë  ê°€ëŠ¥ì„±ì€?**
   - Attrition rate: Primary hit â†’ FDA ìŠ¹ì¸ (0.01%)

**ê¸°ìˆ ì  ì§ˆë¬¸**:

1. **High-content imagingì˜ throughputì€?** (ì‹œê°„ë‹¹ ëª‡ plate?)
2. **ML ëª¨ë¸ì˜ generalizabilityëŠ”?** (ë‹¤ë¥¸ ì„¸ê· ì— ì ìš© ê°€ëŠ¥?)
3. **Automation ìˆ˜ì¤€ì€?** (ì™„ì „ ìë™ vs. ë¶€ë¶„ ìˆ˜ë™)

---

## ğŸ§  ì„¸ì…˜ ì „ì²´ í•µì‹¬ ìš”ì•½

### 10ê°€ì§€ í•µì‹¬ ë©”ì‹œì§€

1. **AutophagyëŠ” "ì¬í™œìš©"ì„ ë„˜ì–´ "í•­ê·  ë¬´ê¸°"ë‹¤**
   - ATG7 ì—†ìœ¼ë©´ NTM ê°ì—¼ ì‹œ ì‚¬ë§
   - mTOR ì–µì œ, AMPK í™œì„±í™”ë¡œ autophagy ìœ ë„
   - Rapamycin, metformin = ê¸°ì¡´ ì•½ë¬¼ ì¬í™œìš© ê°€ëŠ¥

2. **ATG7ì€ ë©´ì—­ ì¡°ì ˆì˜ í•µì‹¬ì´ë‹¤**
   - Inflammasome ê³¼í™œì„± ì–µì œ
   - Type I IFN ì¡°ì ˆ
   - Mitophagy (ë¯¸í† ì½˜ë“œë¦¬ì•„ ì œê±°)ì™€ ì—°ê²°

3. **MycobacteriaëŠ” autophagyë¥¼ íšŒí”¼í•˜ê±°ë‚˜ ì•…ìš©í•œë‹¤**
   - Mtb: ESX-1ìœ¼ë¡œ autophagosome íŒŒê´´
   - M. abscessus: Autophagosome ì•ˆì—ì„œ ìƒì¡´
   - Host-pathogen coevolution

4. **OrganoidëŠ” "ìƒí”¼"ì—ì„œ "ì¡°ì§"ìœ¼ë¡œ ì§„í™”í–ˆë‹¤**
   - 1ì„¸ëŒ€: ìƒí”¼ë§Œ
   - 2ì„¸ëŒ€: Macrophage í¬í•¨ (2024ë…„ í‘œì¤€)
   - 3ì„¸ëŒ€ (ì§„í–‰ ì¤‘): í˜ˆê´€, ì‹ ê²½ í¬í•¨

5. **hPSC-derived MacrophageëŠ” tissue-resident macrophageë¥¼ ì¬í˜„í•œë‹¤**
   - 21ì¼ differentiation protocol
   - Organoidì— í†µí•© ê°€ëŠ¥
   - Phagocytosis, cytokine ë¶„ë¹„ ê¸°ëŠ¥ í™•ì¸

6. **í™˜ì iPSCë¡œ "ê°œì¸ ë§ì¶¤í˜• ì§ˆë³‘ ëª¨ë¸"ì„ ë§Œë“¤ ìˆ˜ ìˆë‹¤**
   - í™˜ì í˜ˆì•¡ â†’ iPSC â†’ Organoid
   - ì•½ë¬¼ ë°˜ì‘ ì˜ˆì¸¡
   - Precision medicineì˜ ë¯¸ë˜

7. **ë§ˆìš°ìŠ¤ëŠ” "ë‹¤ë¥¸ ì¢…"ì´ë‹¤ - ì¸ê°„ ëª¨ë¸ì´ í•„ìˆ˜ë‹¤**
   - ì•½ë¬¼ ê°œë°œ ì‹¤íŒ¨ì˜ 60-70%ê°€ ì¢… ì°¨ì´ ë•Œë¬¸
   - OrganoidëŠ” ë§ˆìš°ìŠ¤ì™€ ì¸ê°„ ì‚¬ì´ì˜ "ë‹¤ë¦¬"
   - ìœ¤ë¦¬ì  ì´ì  (ë™ë¬¼ ì‹¤í—˜ ê°ì†Œ)

8. **Physiologically relevant modelì´ hit rateë¥¼ 15ë°° ë†’ì¸ë‹¤**
   - ì „í†µ HTS: 0.87%
   - ì„¸í¬ ë‚´ ê°ì—¼ ëª¨ë¸: 14.5%
   - ML í†µí•© ì‹œ: 20%+

9. **AI/MLì€ í•­ìƒì œ ë°œê²¬ì˜ ê²Œì„ ì²´ì¸ì €ë‹¤**
   - High-content imaging + ML: Toxic vs. Hit êµ¬ë¶„
   - Deep learning: Virtual screening (90X hit rate)
   - ë¹„ìš©/ì‹œê°„ 90% ì ˆê°

10. **í˜‘ë ¥ì´ í•µì‹¬ì´ë‹¤ (Autophagy + Organoid + AI)**
    - Jo (autophagy) + Kim (organoid) + Lee (HTS/AI)
    - í•™ì œê°„ ìœµí•©: ë©´ì—­í•™ + ì¤„ê¸°ì„¸í¬ + í™”í•™ + AI
    - ì‚°í•™ì—° ì—°ê³„: ëŒ€í•™ + Pasteur + ì œì•½ì‚¬

### ì„¸ì…˜ í›„ ì–»ê²Œ ë  í†µì°°

**ê³¼í•™ì **:
- Autophagyê°€ ë‹¨ìˆœ ì²­ì†Œë¶€ê°€ ì•„ë‹ˆë¼ ë©´ì—­ ì‹œìŠ¤í…œì˜ ì¼ë¶€ì„
- Organoid + immune cells = "living tissue"ì˜ ì¬í˜„
- In vitro ëª¨ë¸ì´ í˜„ì‹¤ì ì¼ìˆ˜ë¡ ì‹ ì•½ ë°œê²¬ ì„±ê³µë¥  ë†’ì•„ì§

**ê¸°ìˆ ì **:
- ATG7 ì¡°ì‘ (KO, overexpression) ë°©ë²•
- hPSC differentiation (macrophage, organoid) í”„ë¡œí† ì½œ
- High-content imaging + ML workflow

**ì‘ìš©ì **:
- Autophagy inducer (rapamycin, metformin) ì„ìƒ ì ìš©
- Patient-derived organoidë¡œ ê°œì¸ ë§ì¶¤ ì¹˜ë£Œ
- AI-guided compound screeningìœ¼ë¡œ ê°œë°œ ê¸°ê°„ ë‹¨ì¶•

**ê°œì¸ì ** (í¬ë‹¥):
- ì²¨ë‹¨ ê¸°ìˆ  (iPSC, organoid, ML)ì˜ ê°€ì¹˜
- í˜‘ë ¥ì˜ ì‹œë„ˆì§€ (3ê°œ ê·¸ë£¹ì´ í•¨ê»˜í•˜ë©´ ë” ê°•ë ¥)
- ì‚°í•™ì—° ê²½ë ¥ ê²½ë¡œ (Institut Pasteur Korea ê°™ì€ ê³³)

---

## ğŸ“š ì‚¬ì „ ì½ê¸° ìë£Œ

### í•„ìˆ˜ ë¦¬ë·° ë…¼ë¬¸

#### 1. Autophagyì™€ ê°ì—¼ (ìµœì‹  ë¦¬ë·°)

```
ğŸ“„ Frontiers in Cellular and Infection Microbiology (2025)
"Autophagy in mycobacterial infections: molecular mechanisms,
 host-pathogen interactions, and therapeutic opportunities"
https://www.frontiersin.org/journals/cellular-and-infection-microbiology/
articles/10.3389/fcimb.2025.1640647/full

í•µì‹¬ ë‚´ìš©:
- Autophagy ë©”ì»¤ë‹ˆì¦˜ ìƒì„¸
- Mtb, NTMì˜ íšŒí”¼ ì „ëµ
- Host-directed therapy ì „ëµ
- ì„ìƒ ê°€ëŠ¥ì„±

ì½ê¸° ì‹œê°„: 60ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜…
```

#### 2. Organoid ê¸°ìˆ  (2024 ì—…ë°ì´íŠ¸)

```
ğŸ“„ Cell Stem Cell (2024)
"Human vascularized macrophage-islet organoids to model
 immune-mediated pancreatic Î² cell pyroptosis upon viral infection"

í•µì‹¬ ë‚´ìš©:
- hPSC differentiation í”„ë¡œí† ì½œ
- Macrophage integration ë°©ë²•
- Infection modeling (SARS-CoV-2)
- scRNA-seq ë¶„ì„

ì½ê¸° ì‹œê°„: 90ë¶„ (ë³µì¡)
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜…
```

#### 3. AI in Drug Discovery

```
ğŸ“„ Nature Biotechnology (2025)
"Deep learning speeds the search for new antibiotic scaffolds"

í•µì‹¬ ë‚´ìš©:
- DL model architecture
- Training data (90,000 compounds)
- Virtual screening (1.9M molecules)
- Hit rate 90X í–¥ìƒ

ì½ê¸° ì‹œê°„: 45ë¶„
ì¤‘ìš”ë„: â˜…â˜…â˜…â˜…â˜†
```

### ì‚¬ì „ ì½ê¸° (ì—°ì‚¬ ì£¼ìš” ë…¼ë¬¸)

```
1. Jo EK: Nature Commun (2025) - ATG7 NTM ê°ì—¼
2. Kim JH: Cell Stem Cell (2024) - VMI organoid
3. Lee H: PLoS Comput Biol (2024) - ML HTS

ê° 30-60ë¶„, ë°œí‘œ ì´í•´ì— í•„ìˆ˜
```

---

## ğŸ¤ ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸ (30ê°œ)

### ê³¼í•™ì  ì§ˆë¬¸ (10ê°œ)

**Q1**: Rapamycinìœ¼ë¡œ autophagy ìœ ë„ ì‹œ, ë©´ì—­ì–µì œ ë¶€ì‘ìš©ê³¼ í•­ê·  íš¨ê³¼ì˜ balanceëŠ” ì–´ë–»ê²Œ ë§ì¶”ë‚˜?

**Q2**: M. abscessusê°€ autophagosome ì•ˆì—ì„œ ìƒì¡´í•˜ëŠ” ë©”ì»¤ë‹ˆì¦˜ì€ ë¬´ì—‡ì¸ê°€? (ë‹¤ë¥¸ mycobacteriaì™€ì˜ ì°¨ì´)

**Q3**: Organoidì˜ alveolar macrophageê°€ ì§„ì§œ in vivo AMê³¼ transcriptomeì´ ìœ ì‚¬í•œê°€?

**Q4**: í™˜ì iPSC-derived organoidì—ì„œ HLA íƒ€ì…ì´ ê°ì—¼ ë°˜ì‘ì— ì˜í–¥ì„ ì£¼ëŠ”ê°€?

**Q5**: GFP-S. aureusì˜ fitnessê°€ WTì™€ ê°™ì€ê°€? (in vivo virulence)

**Q6**: Intracellular bacteriaì™€ extracellular bacteriaì˜ ì•½ë¬¼ ê°ìˆ˜ì„± ì°¨ì´ëŠ” ëª‡ ë°°ì¸ê°€?

**Q7**: Autophagyì™€ inflammasome crosstalkì˜ ë¶„ì ë©”ì»¤ë‹ˆì¦˜ì€? (NLRP3, AIM2)

**Q8**: Organoid biofilm í˜•ì„±ì´ ê°€ëŠ¥í•œê°€? (P. aeruginosa, S. aureus)

**Q9**: ML ëª¨ë¸ì´ novel scaffoldë¥¼ ì˜ˆì¸¡í•  ìˆ˜ ìˆë‚˜? (known pharmacophore ì™¸)

**Q10**: Vascularized organoidì—ì„œ ì•½ë¬¼ PK/PD ì˜ˆì¸¡ì´ ê°€ëŠ¥í•œê°€?

### ê¸°ìˆ /ë°©ë²•ë¡  ì§ˆë¬¸ (10ê°œ)

**Q11**: ATG7 conditional KO ë§ˆìš°ìŠ¤ ì œì‘ ê¸°ê°„ê³¼ ë¹„ìš©ì€?

**Q12**: hPSC macrophage differentiation íš¨ìœ¨ì€? (ëª‡ %ê°€ CD14+?)

**Q13**: Organoid í¬ê¸° ê· ì¼ì„±ì„ ì–´ë–»ê²Œ í™•ë³´í•˜ë‚˜? (batch variation)

**Q14**: High-content imaging throughputì€? (í•˜ë£¨ ëª‡ plate?)

**Q15**: ML feature engineeringì—ì„œ ê°€ì¥ ì¤‘ìš”í•œ featureëŠ”?

**Q16**: Autophagy flux ì¸¡ì • ì‹œ bafilomycin A1 ìµœì  ë†ë„ëŠ”?

**Q17**: Organoid ì¥ê¸° ë°°ì–‘ ê°€ëŠ¥ ê¸°ê°„ì€? (ëª‡ ê°œì›”?)

**Q18**: GFP signal quantification ë°©ë²•ì€? (plate reader vs. confocal)

**Q19**: scRNA-seq cell ìˆ˜ëŠ”? (í†µê³„ì  power)

**Q20**: In vivo validation ì‹œ ë§ˆìš°ìŠ¤ strain ì„ íƒ ê¸°ì¤€ì€?

### ì‘ìš©/ì‚°ì—… ì§ˆë¬¸ (5ê°œ)

**Q21**: Rapamycin ë˜ëŠ” metforminì˜ Mtb/NTM ì„ìƒì‹œí—˜ ê³„íšì´ ìˆë‚˜?

**Q22**: Patient-derived organoid screening ë¹„ìš©ì€? (í™˜ì 1ëª…ë‹¹)

**Q23**: Institut Pasteur Koreaì˜ HTS facility ì™¸ë¶€ ì´ìš© ê°€ëŠ¥í•œê°€?

**Q24**: Hit compoundì˜ IPëŠ” ëˆ„êµ¬ì—ê²Œ? (ëŒ€í•™ vs. ì—°êµ¬ì†Œ vs. ì œì•½ì‚¬)

**Q25**: AI-guided screening platform ìƒìš©í™” ê³„íšì€?

### êµìœ¡/ì§„ë¡œ ì§ˆë¬¸ (3ê°œ)

**Q26**: Organoid ê¸°ìˆ ì„ ë°°ìš°ë ¤ëŠ” í¬ë‹¥ì—ê²Œ ì¶”ì²œí•˜ëŠ” êµìœ¡ ê³¼ì •ì€?

**Q27**: Institut Pasteur Koreaì—ì„œ í¬ë‹¥ ì±„ìš©í•˜ë‚˜? (ì¡°ê±´ì€?)

**Q28**: í•™ì œê°„ ì—°êµ¬ (ë©´ì—­ + iPSC + AI)ë¥¼ ì‹œì‘í•˜ë ¤ë©´ ì–´ë–¤ ìˆœì„œë¡œ?

### ì² í•™ì /ë¯¸ë˜ ì§ˆë¬¸ (2ê°œ)

**Q29**: Organoidê°€ ë§ˆìš°ìŠ¤ë¥¼ ì™„ì „íˆ ëŒ€ì²´í•  ìˆ˜ ìˆë‚˜? (ìœ¤ë¦¬, ê·œì œ)

**Q30**: AIê°€ í•­ìƒì œ ê°œë°œì„ ì™„ì „ ìë™í™”í•  ìˆ˜ ìˆë‚˜? (10ë…„ í›„)

---

## ğŸ¤ ë„¤íŠ¸ì›Œí‚¹ ìš°ì„ ìˆœìœ„

### Tier 1: ìµœìš°ì„  ì»¨íƒ

#### Eun-Kyeong Jo (Chungnam National University)

**ë°°ê²½**:
- Professor, Department of Microbiology
- Leader, Infection Control Research Group
- 2025ë…„ Nature Commun (ATG7-NTM)

**ì ‘ê·¼ ì „ëµ**:
- ë°œí‘œ ì§í›„ autophagy ê´€ë ¨ êµ¬ì²´ì  ì§ˆë¬¸
- Lab visit ìš”ì²­ (ëŒ€ì „ ì†Œì¬)
- Collaboration: Autophagy assay protocol

**ë…¼ì˜ ì£¼ì œ**:
- í¬ë‹¥: ATG7 activator ê°œë°œ, grant ê³µë™ ì‹ ì²­
- í•™ìƒ: Autophagy training, ì„ë°•ì‚¬ ê³¼ì •

#### Jung-Hyun Kim (Ajou University)

**ë°°ê²½**:
- Professor, School of Pharmacy
- Organoid + infection expert
- 2024ë…„ Cell Stem Cell

**ì ‘ê·¼ ì „ëµ**:
- Organoid ì œì‘ ë°©ë²•ë¡  ë¬¸ì˜
- í˜‘ë ¥: Patient iPSC organoid screening
- Lab visit (ìˆ˜ì› ì†Œì¬)

**ë…¼ì˜ ì£¼ì œ**:
- í¬ë‹¥: hPSC differentiation training
- ì‚°ì—…: Organoid platform licensing

#### Hyunjung Lee (Institut Pasteur Korea)

**ë°°ê²½**:
- Senior Researcher
- HTS + AI expert
- ì„±ë‚¨ íŒêµ ì†Œì¬ (ì ‘ê·¼ ì‰¬ì›€)

**ì ‘ê·¼ ì „ëµ**:
- HTS facility ì´ìš© ê°€ëŠ¥ì„±
- ML collaboration
- Screening service

**ë…¼ì˜ ì£¼ì œ**:
- í•™ìƒ: Internship
- í¬ë‹¥: Joint project
- ì‚°ì—…: Contract screening

### Tier 2: ê´€ë ¨ ë¶„ì•¼ ì—°êµ¬ì

- Autophagy ì—°êµ¬ì (êµ­ë‚´): ì„œìš¸ëŒ€, KAIST
- iPSC ì—°êµ¬ì: ì—°ì„¸ëŒ€, ê°€í†¨ë¦­ëŒ€
- AI drug discovery: KISTI, ì œì•½ì‚¬ AIíŒ€

### Tier 3: ì‚°ì—…ê³„

- Organoid íšŒì‚¬: Organoid Sciences (íŒêµ)
- AI drug discovery: Standigm, Deargen
- CRO: PharmAbcine, Medpacto

---

## âš¡ ì„¸ì…˜ ë‹¹ì¼ ì²´í¬ë¦¬ìŠ¤íŠ¸

### D-1 (10ì›” 29ì¼)

**ì§€ì‹ ì¤€ë¹„**:
- [ ] ë°°ê²½ ìë£Œ 2ì°¨ ì •ë…
- [ ] ì—°ì‚¬ ë…¼ë¬¸ abstract ì½ê¸° (3í¸)
- [ ] ì§ˆë¬¸ 3ê°œ ì¤€ë¹„

**ë¬¼ë¦¬ì  ì¤€ë¹„**:
- [ ] ëª…í•¨ 30ì¥
- [ ] ë…¸íŠ¸ë¶/íƒœë¸”ë¦¿ ì¶©ì „
- [ ] ì„¸ì…˜ ì•ŒëŒ (15:00)

### ì„¸ì…˜ ì¤‘ (15:10-16:25)

- [ ] í•µì‹¬ ìŠ¬ë¼ì´ë“œ ì‚¬ì§„
- [ ] ì§ˆë¬¸ 1-2ê°œ
- [ ] ë„¤íŠ¸ì›Œí‚¹ ëŒ€ìƒ íŒŒì•…

### ì„¸ì…˜ ì§í›„ (16:25-16:40, Break)

- [ ] ì—°ì‚¬ ì ‘ê·¼ (5ë¶„ ëŒ€í™”)
- [ ] ëª…í•¨ êµí™˜
- [ ] ë©”ëª¨ ì •ë¦¬

### D+1 (10ì›” 31ì¼)

- [ ] Follow-up ì´ë©”ì¼ (3ëª…)
- [ ] Lab visit ì¼ì • ì¡°ìœ¨

---

## ğŸ“Š ì˜ˆìƒ í•™ìŠµ ì„±ê³¼

### ì§€ì‹ (Knowledge)

**Level 1**: Autophagy, organoid, HTS ê¸°ë³¸ ê°œë…
**Level 2**: ATG7 ë©”ì»¤ë‹ˆì¦˜, hPSC differentiation, ML workflow
**Level 3**: Host-directed therapy ì „ëµ, patient-derived model, AI drug discovery

### ê¸°ìˆ  (Skills)

- Autophagy assay (LC3, p62)
- Organoid ì œì‘
- High-content imaging + ML

### íƒœë„ (Attitude)

- í•™ì œê°„ ìœµí•©ì˜ ê°€ì¹˜
- í™˜ì ì¤‘ì‹¬ ì—°êµ¬
- AI í™œìš© í•„ìˆ˜

### ë„¤íŠ¸ì›Œí¬

- 3ëª… ì—°ì‚¬ ì—°ê²°
- Institut Pasteur Korea ì ‘ì 
- Organoid ì»¤ë®¤ë‹ˆí‹°

### ì‘ìš©

- HDT í”„ë¡œì íŠ¸ ì•„ì´ë””ì–´
- Organoid screening ê³„íš
- AI collaboration êµ¬ìƒ

---

**ë¬¸ì„œ ì‘ì„±**: 2025-10-29
**ë²„ì „**: 2.0
**í•™íšŒ**: IAMRT 2025

**ì„¸ì…˜ ì°¸ì„ ì „ ì´ ë¬¸ì„œë¥¼ ìµœì†Œ 2íšŒ ì •ë…í•˜ê³ , ì§ˆë¬¸ 3ê°œë¥¼ ì¤€ë¹„í•˜ì„¸ìš”!**

**Good luck! ğŸ‰ğŸ”¬**